The Patent Finder
CP

Collegium Pharmaceutical, Inc.

Filings on record here from 2001, where this site's data begins
OverviewNotableFeesChangesFamiliesPatent listSources & methods

Seven patents currently held, every record listed here

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1 more record may belong here and awaits a decision; it is not counted.

The next term ends in Apr 2028. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
3
Ending by 2030
Apr 2028
Next term end
4
Patent families

When these terms end

Each bar runs from grant to computed term end. 2010 to 2036.
US 11,344,512 Titration of Tapentadol Apr 21, 2028
US 8,536,130 Use of 1-Phenyl-3-Dimethylamino-PROPANE Compounds for Treating Neuropathic Pain Sep 22, 2028
US 7,771,707 Abuse-Deterrent Drug Formulations Oct 9, 2028
US 9,737,530 Process of Making Stable Abuse-Deterrent Oral Formulations Sep 2, 2036
US 9,968,598 Process of Making Stable Abuse-Deterrent Oral Formulations Sep 2, 2036
US 10,188,644 Process of Making Stable Abuse-Deterrent Oral Formulations Sep 2, 2036
US 10,646,485 Process of Making Stable Abuse-Deterrent Oral Formulations Sep 2, 2036
201520202025203020352036
2 pending applications: term is not computable until grant.Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Nov 12, 2027
    The maintenance fee for Process of Making Stable Abuse-Deterrent Oral Formulations (US 10,646,485) comes due Nov 12, 2027. Unpaid by May 12, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

What they patent

Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.

Showing 1 to 7 of 7

PatentTitleStatusExpiresConfidence
US 11,344,512Titration of Tapentadol
In force
 · Medium confidence
In forceMedium confidence
US 8,536,130Use of 1-Phenyl-3-Dimethylamino-PROPANE Compounds for Treating Neuropathic Pain
In force
 · Medium confidence
In forceMedium confidence
US 7,771,707Abuse-Deterrent Drug Formulations
In force
 · High confidence
In forceHigh confidence
US 9,737,530Process of Making Stable Abuse-Deterrent Oral Formulations
In force
 · High confidence
In forceHigh confidence
US 9,968,598Process of Making Stable Abuse-Deterrent Oral Formulations
In force
 · High confidence
In forceHigh confidence
US 10,188,644Process of Making Stable Abuse-Deterrent Oral Formulations
In force
 · High confidence
In forceHigh confidence
US 10,646,485Process of Making Stable Abuse-Deterrent Oral Formulations
In force
 · High confidence
In forceHigh confidence
Also on record, not counted in the 7: 25 patents ended · 2 applications pending · 50 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited